β-Blocker Selection in Long QT Syndrome with First-Degree AV Block
In a patient with congenital long QT syndrome and first-degree AV block, nadolol remains the preferred β-blocker despite the conduction abnormality, as β-blockers do not significantly worsen AV conduction in first-degree block and nadolol provides superior arrhythmic event protection compared to other agents. 1
Primary Recommendation: Nadolol
The 2023 Canadian Cardiovascular Society guidelines explicitly state that nadolol is the β-blocker of choice for intermediate and high-risk LQTS patients (particularly those with QTc ≥500 ms or prior events), providing greater protection than β-1 selective agents like atenolol and metoprolol 1. This recommendation holds even in the presence of first-degree AV block because:
- First-degree AV block is not a contraindication to β-blocker therapy in LQTS - the mortality benefit from preventing ventricular arrhythmias far outweighs concerns about mild PR prolongation
- β-blockers minimally affect the absolute QT interval at heart rates of 60-100 bpm 1
- The typical dosing is 1-1.5 mg/kg once daily in adults (twice daily in children) 1
Alternative Option: Bisoprolol
For lower-risk patients or those who cannot tolerate nadolol due to side effects (particularly fatigue), bisoprolol represents a reasonable alternative 1. The guidelines note that:
- Bisoprolol is generally better tolerated than nadolol
- Breakthrough arrhythmic events are rare with bisoprolol despite its β-1 selectivity
- This would be appropriate for patients with QTc <500 ms and no prior events
Critical Implementation Strategy
Start at low doses with gradual uptitration to minimize both side effects and any potential worsening of AV conduction 1. Monitor:
- Serial ECGs to assess PR interval changes
- Heart rate response (target maximum heart rate <150 bpm on exercise testing)
- Symptoms of bradycardia or higher-degree AV block
Agents to Avoid
Atenolol and metoprolol should be avoided as they provide inferior protection against arrhythmic events compared to nonselective agents 1. Recent network meta-analysis data from 2025 confirms nadolol's superiority, particularly in LQT1 (RR=0.59 vs propranolol) and demonstrates dose-dependent benefit in LQT2 and LQT3 2.
Special Consideration: 2:1 AV Block
The question specifies first-degree block, but if the patient had 2:1 AV block (a much more severe presentation), the approach differs substantially:
- β-blockers remain essential but require adjunctive therapy
- Mexiletine (sodium channel blocker) combined with propranolol has shown success 3, 4
- Pacemaker placement is typically required 4, 5
- Recent case reports support continuous IV lidocaine as bridge therapy 6
However, with isolated first-degree AV block, pacing is not indicated and standard β-blocker monotherapy is appropriate.
Common Pitfall
Do not withhold β-blocker therapy due to first-degree AV block in LQTS patients - the risk of sudden cardiac death from untreated LQTS vastly exceeds any risk from mild PR prolongation. The 2017 AHA/ACC/HRS guidelines emphasize that β-blockade is the cornerstone of LQTS therapy 7, and this applies regardless of first-degree conduction delay.